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Renal vascular responses to captopril and to candesartan in The unambiguous effectiveness of angiotensin-convert-
patients with type 1 diabetes mellitus. ing enzyme (ACE) inhibition with captopril in changing
Background. Enhanced renal vasodilator responses to an- the natural history of nephropathy in patients with typegiotensin-converting enzyme (ACE) inhibition in diabetes mel-
1 diabetes mellitus has focused attention on the mecha-litus despite a normal or low plasma renin activity level have
nisms by which the ACE inhibitor works [1]. Studies insuggested intrarenal activation of the renin-angiotensin system
in this disease. There is, however, a continuing debate as to humans and in animals have suggested that renal hemo-
the mediators of the renal hemodynamic response to ACE dynamics contribute to the pathogenesis [2–11]. For
inhibition–reduced angiotensin II formation or pathways in- these reasons, a number of studies have been performedvolving kinins, prostaglandins, and nitric oxide.
on the acute renal hemodynamic response to ACE inhi-Methods. Twelve patients with type 1 diabetes mellitus of
bition in patients with type 1 diabetes mellitus [12–21].18 6 3.2 (SEM) years of duration (7 females and 5 males,
ages 17 to 50, 32 6 4.0 years) who were free of sustained The mechanism responsible for the acute and often dra-
microalbuminuria and on a high-salt diet were given the ACE matic vasodilator response to captopril has not been
inhibitor captopril (25 mg orally) on one day and the AT1 clearly defined. One possibility involves a reduction inreceptor blocker candesartan (16 mg orally) on another day.
angiotensin II (Ang II) formation, but there is an alterna-Renal plasma flow (RPF) and glomerular filtration rate were
tive possibility involving activation of vasodilator path-measured before and for four hours after administration.
Results. Both drugs caused a significant increase in RPF ways via bradykinin accumulation, prostaglandin forma-
(captopril 574 6 26 to 625 6 37 mL/min/1.73 m2, P 5 0.008; tion, and activation of nitric oxide synthesis [22].
candesartan 577 6 26 to 643 6 37, P 5 0.004). There was a In this study, we have assessed the mechanism respon-highly significant correlation between the responses to capto-
sible for the accentuated renal hemodynamic responsepril and to candesartan (r 5 0.86, P , 0.001). Seven subjects
to captopril in patients with type 1 diabetes mellitus byhad an RPF response to captopril that was accentuated (90 6
13 mL/min/1.73 m2), while five had a response that was normal comparing that response to the response induced by an
(24 6 9). There was no significant change in glomerular filtra- Ang II subtype 1 (AT1) receptor blocker, candesartan.
tion rate on either drug. Our hypothesis was that the responses would correlateConclusion. The remarkable rise in RPF in response to cap-
well if the dominant action of captopril involved block-topril and candesartan despite high-salt balance suggests the
ade of Ang II formation, but would likely be discordantintrarenal activation of the renin-angiotensin system in diabetes
that is not reflected in plasma renin levels. The high correlation if the alternative action of captopril via vasodilator path-
between the renal hemodynamic response to captopril and to ways was responsible.
candesartan indicates that reduced angiotensin II formation is
the main mechanism of action of the ACE inhibitor.
METHODS
Subjects and protocols
We studied 12 men and women with type 1 diabetes
mellitus who ranged in age from 17 to 50 years (mean 6
SEM, 32 6 4.0). The duration of diabetes ranged fromKey words: ACE inhibition, renin-angiotensin system, AT1 receptor
blocker, renal plasma flow, hemodynamics, vascular tone. 2 to 40 years (mean 18 6 3.2). Type 1 diabetes mellitus
was diagnosed according to accepted guidelines [23]. AllReceived for publication May 26, 2000
were otherwise healthy, normotensive, and free of sus-and in revised form September 28, 2000
Accepted for publication October 20, 2000 tained microalbuminuria and other complications of dia-
betes. The subjects were studied during admission to aÓ 2001 by the International Society of Nephrology
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metabolic ward at the General Clinical Research Center ated immediately at a rate of 12 and 30 mg/min, respec-
tively, with an IMED pump (Alaris Medical System,(GCRC) at the Brigham and Women’s Hospital, where
balance was achieved on a controlled diet. San Diego, CA, USA). This achieved a plasma PAH
concentration in the middle of the range in which tubularAll subjects were placed on a high-salt isocaloric diet
starting two days prior to admission and continuing secretion dominates excretion. At this plasma level of
PAH, clearance is independent of plasma concentrationthroughout the hospitalization, with a daily sodium in-
take of 200 mmol. Daily dietary potassium (100 mmol) and represents approximately 90% of RPF when cor-
rected for individual body surface area. Likewise, at theand fluid intake (2500 mL) were constant. Twenty-four–
hour urine samples were collected daily and analyzed for level of plasma inulin achieved, inulin clearance reflects
GFR. RPF and GFR determinations were made at base-sodium, potassium, creatinine, and protein. The protocol
was approved by the Human Subjects Committee of the line and at 45-minute intervals thereafter until 225 min-
utes (,4 h) while the subjects were supine.institution, and written-informed consent was obtained
from each subject.
Laboratory procedures
Renal hemodynamic and hormonal responses to Blood samples were collected on ice and spun immedi-
captopril and candesartan ately, and the plasma was frozen until assay. Urinary
and serum sodium and potassium levels were measuredEach subject participated in two experimental days.
On the morning of each study day, an intravenous cathe- using the ion-selective electrode. PAH and inulin were
measured using an autoanalyzer technique. Plasma reninter was placed in each arm of each subject, one for
infusion of p-aminohippurate (PAH), inulin, and dex- activity (PRA) and aldosterone were determined by ra-
dioimmunoassay [24, 25]. Hemoglobin A1C (HbA1C)trose 5% in water and the other for blood sampling. A
third intravenous line was placed for continuous infusion was measured by high-performance liquid chromatogra-
of insulin that was started at 0.015 U/kg/h. Blood glucose phy. The normal range is 4.4 to 6.3%.
was measured every 30 minutes (Precision PCX; Abbott
AnalysesLaboratories, Chicago, IL, USA). The insulin infusion
was adjusted to maintain blood glucose below the renal Group means were calculated with the SEM as the
threshold but without inducing hypoglycemia, at levels index of dispersion. For renal hemodynamic data, the
of 100 to 140 mg/dL. The subjects were supine and had baseline value taken was the average of three predrug
been fasting for at least eight hours. Each study day determinations, and the peak response was the average
began with a 60-minute baseline infusion of PAH and of the two highest consecutive values.
inulin prior to drug administration to determine baseline Pearson’s correlation was used to test the association
renal plasma flow (RPF) and glomerular filtration rate of the renal response to candesartan with the response
(GFR), respectively. Hormonal measurements were to captopril. Paired t-test was used to compare the renal
made on blood samples obtained at baseline and at four vascular and PRA responses to captopril and candesar-
and eight hours after drug administration while the sub- tan. The subjects were then divided into two groups:
jects were lying supine. those in whom the RPF response to captopril was normal
The study was designed to compare the renal hemody- and those in whom the response was accentuated to de-
namic response to captopril and to candesartan. On the termine whether there were differences in renin activity.
first morning, the patients received captopril (25 mg Fisher’s exact test, t-test, and Mann–Whitney rank sum
orally). On the next morning, the patients received can- test were used to compare the characteristics and the renal
desartan (16 mg orally). These doses were chosen be- hemodynamic and PRA responses of these two groups.
cause both represent the top of the relationship between Analysis of covariance (ANCOVA) was performed to
dose and RPF response. account for possible confounding effects of baseline char-
Blood pressure was recorded during each infusion acteristics on RPF response to the two drugs.
by an automatic recording device (Dinamap; Critikon,
Tampa, FL, USA) at five-minute intervals.
RESULTS
Renal clearance studies Baseline characteristics of the subjects are listed in
Table 1. The high-salt balance, as evidenced by a 24-hourPara-aminohippurate (PAH; Merck, Sharp & Dohme,
urine sodium excretion of 254 6 34.9 mEq, resulted inRahway, NJ, USA) and inulin (Inutest; Fresenius Pharma
suppression of the renin-angiotensin system (RAS) atAustria GmbH, Linz, Austria) clearances were assessed
baseline, as anticipated.after metabolic balance was achieved. A control blood
The average blood glucose achieved during the capto-sample was drawn, and then loading doses of PAH
pril study was not significantly different from that during(8 mg/kg) and inulin (50 mg/kg) were given intrave-
nously. A constant infusion of PAH and inulin was initi- the candesartan study (119 6 35 vs. 127 638 mg/dL, P 5
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Table 1. Baseline characteristics of the 12 subjects in
high-sodium balance
Parameters Mean6SEM
Age years 3264.0
Sex distribution male/female 5/7
Race All Caucasian
Body mass index kg/m2 2561.0
Systolic blood pressure mm Hg 11464.4
Diastolic blood pressure mm Hg 6763.8
Duration of diabetes years 1863.2
Hemoglobin A1C % 760.4
Fasting blood sugar mg/dL 12469.7
Serum creatinine mg/dL 0.8260.04
Serum sodium mEq/L 13860.7
Serum potassium mEq/L 4.460.1
24-Hour urine sodium mEq 254634.9
24-Hour urine potassium mEq 5965.9
Plasma renin activity ng Ang I/mL/h 0.4360.08
Plasma aldosterone ng/mL 3.360.6
Fig. 1. Time course of the renal vascular response to captopril (d) and
candesartan (s) in patients with type 1 diabetes mellitus.
Table 2. Baseline renal hemodynamics and the responses to
captopril and candesartan (mean6SEM)
Captopril vs.
candesartan
Captopril Candesartan P value
Renal plasma flow
mL/min/1.73 m2
Baseline 574626 577626 0.69
Peak 625637 643637 0.09
Response 51615 66619 0.13
Glomerular filtration rate
mL/min/1.73 m2
Baseline 12964 12563 0.06
Peak 13064 12763 0.22
Response 162 262 0.63
0.38). RPF at baseline was not significantly different for
the two drugs (Table 2). Both captopril and candesartan
Fig. 2. Correlation between change in renal plasma flow (RPF) incaused a rise in RPF with time (Fig. 1). Captopril caused
response to captopril and to candesartan. Note the striking correlation
a significant increase in RPF of 51 6 15 mL/min/1.73 m2 (r 5 0.86) between the responses to the two agents. In five of the seven
patients with an accentuated response, the response to candesartan(peak vs. baseline RPF, P 5 0.008). Candesartan likewise
exceeded the response to captopril. Thus, it is unlikely that factorsinduced a substantial rise in RPF of 66 6 19 mL/min/
beyond Ang II are responsible for the accentuated response (N 5 12;
1.73 m2 (P 5 0.004). The response to captopril was not P , 0.001).
significantly different from the response to candesartan
(P 5 0.13); however, the time to peak was different
for the two drugs. Captopril had achieved the greatest
to the two drugs (P 5 0.239). When baseline RPF, base-response by 90 to 135 minutes, while the response to
line GFR, and baseline PRA were added as covariates,candesartan was still rising at 225 minutes. Baseline and
the responses remained not significantly different frompeak GFRs were likewise not significantly different be-
each other (P 5 0.345).tween the two drugs. There was no significant change in
Plasma renin activity levels were equally suppressedGFR either in response to captopril or to candesartan
at baseline on both days (Table 3). The PRA response to(P 5 0.74 and P 5 0.45, respectively).
captopril did not differ from the response to candesartanThe RPF responses to captopril and to candesartan
(Table 3), although a trend toward a larger response toshowed remarkable concordance (r 5 0.86, P , 0.001;
candesartan was evident.Fig. 2). With an r2 of 0.74, 74% of the variation in the
The RPF response to captopril in normal humansresponse to captopril was accounted for on the basis of
when the renin system is suppressed by a high-salt dietthe response to candesartan. Using ANCOVA, there
was no significant difference between the RPF response is less than 30 mL/min/1.73 m2 [26, 27]. On that basis,
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Table 3. Baseline plasma renin activity (PRA) values
(ng Ang I/mL/h) and the responses to captopril and candesartan
(mean6SEM)
Captopril vs.
candesartan
Captopril Candesartan P value
Baseline 0.4360.08 0.5260.12 0.18
Peak 1.0560.55 5.7563.20 0.14
Response 0.6260.47 5.2363.11 0.14
the response to captopril in the 12 patients with type 1
diabetes mellitus was normal in five and accentuated in
the other seven. In the five patients in whom the response
to captopril was minimal, the response to candesartan
was also minimal. In the seven patients in whom the
Fig. 3. Baseline and peak renal plasma flow (RPF) response to cande-
response to captopril was accentuated, the response to sartan and to captopril in the patients with type 1 diabetes mellitus
subdivided according to whether the renal response to captopril wascandesartan was accentuated equally or more (Fig. 2).
in the normal range or accentuated. Note that baseline RPF was signifi-The seven patients with the accentuated response did
cantly higher in the patients in whom the renal hemodynamic response
not differ from the five with normal RPF responses in to captopril, and to candesartan, was accentuated. Symbols are: (d)
accentuated response; (s) normal response.terms of gender (P 5 1.000), age (30 6 4.7 vs. 36 6
8.9 years, P 5 0.52), fasting blood sugar (123 6 17
vs. 123 6 7 mg/dL, P 5 0.99), or HbA1C (7.3 6 0.5 vs.
6.4 6 0.5%, P 5 0.22) nor in terms of the average blood
reaches its peak in the first four hours and is sustainedglucose level achieved following captopril (120 6 8 vs.
for the next four hours [31]. The correlation coefficient117 6 8 mg/dL, P 5 0.82) or candesartan (128 6 10
between the RPF responses to captopril and to candesar-vs. 127 6 10 mg/dL, P 5 0.94). Moreover, the two groups
tan was 0.86 (P , 0.001). As candesartan specificallydid not differ either in baseline PRA or in PRA response
blocks the AT1 receptor to prevent the action of Ang II,(Table 4). However, there was a significant difference
this implies that the dominant effect of ACE inhibitionin baseline RPF between the groups. On both study days,
was likewise on the Ang II pathway. Thus, it is unlikelythe patients who showed an accentuated RPF response
that other pathways, such as those involving bradykinin,had higher baseline RPF than those who showed a nor-
prostaglandin, and nitric oxide, contribute substantiallymal response (captopril 623 6 26 vs. 505 6 44 mL/min/
to the renal response to ACE inhibition in accord with1.73 m2, P 5 0.04; candesartan 625 6 28 vs. 509 6 32,
other observations in humans [32]. The same conclusionP 5 0.02; Fig. 3).
was reached in a study by Gansevoort, De Zeeuw, and
De Jong in normal subjects, in whom the Ang II antago-
DISCUSSION nist losartan had effects on renal hemodynamics similar
to the ACE inhibitor enalapril [33]. However, unlikeOur goal was to ascertain whether or not the mecha-
their study, ours includes a patient-by-patient analysisnism for the enhanced renal hemodynamic response to
rather than a comparison of group means.ACE inhibition in patients with type 1 diabetes mellitus
Although indirect, this approach to testing our hypoth-was predominantly caused by reduced Ang II formation
esis is one of the few methods available in humans. In[12–21]. Few studies have attempted to delineate this
two earlier studies, the same principle of a shared actionmechanism in humans, and these have largely focused
of two pharmacologically distinct drugs—an ACE inhibi-on normal subjects on a low-salt diet in order to activate
tor and an Ang II antagonist—was also involved in ex-the RAS [28–30]. This study in diabetic patients on a
plaining the renal hemodynamic effects of ACE inhibi-high-salt diet has therapeutic implications, given that
tion [28, 29]. The only other mechanistic study in humansthis population has been shown to benefit from ACE
involved administration of captopril alone, captopril plusinhibition and that their typical diet more likely includes
the bradykinin receptor antagonist, icatibant (HOE 140),liberal salt intake rather than rigid sodium restriction.
or losartan alone. Renal vascular resistance decreasedBoth captopril and candesartan induced significant in-
to a similar extent in all three phases, indicating thatcreases in RPF. Because RPF determinations were not
bradykinin did not play a significant role in the renalmade beyond 225 minutes, it might seem that the peak
response to ACE inhibition [30].response to candesartan was not captured. However, we
have previously shown that the RPF response already One possible limitation of this study involves the fact
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Table 4. Renal plasma flow (mL/min/1.73 m2) and plasma renin activity (ng Ang I/mL/h) on captopril and candesartan and on high-salt
diet among the normal-RPF and accentuated-RPF response groups (mean6SEM)
Type 1 DM
Type 1 DM Type 1 DM accentuated vs.
Normal normal RPF accentuated RPF normal RPF
subjects response group response group response group
Captopril
RPF response 7621 2469 90 613 ,0.001
Baseline PRA 0.360.1 0.3460.08 0.4960.14 0.43
Peak PRA 3.461.1 0.6260.17 1.4961.17 0.46
PRA response 3.1 0.2860.09 1.0061.01 0.42
Candesartan
RPF response 93623a 8615 108617 ,0.001
Baseline PRA 0.4560.05a 0.3860.13 0.6160.19 0.53
Peak PRA 10.6263.96a 1.1060.55 9.6266.41 0.17
PRA response 10.1763.60a 0.7260.43 9.0166.24 0.24
a Unpublished results from our laboratory
that the sequence of captopril and candesartan adminis- sibility of intrarenal activation of the RAS that is not
reflected in plasma levels. A similar pattern occurs intration was not random. Our goal was to study the re-
sponse to the two agents in as short an interval as possi- normal humans when hyperglycemia enhances the renal
hemodynamic response to pharmacological interruptionble, and candesartan has a duration of action of at least
48 hours [31]. Captopril, on the other hand, shows a of the renin system, yet PRA remains unchanged [26, 27].
Another feature of the renal hemodynamic responseresponse that fades rapidly after two to three hours [34].
For that reason, captopril was administered first in each to hyperglycemia was also evident in our patients. Hyper-
glycemia induced acutely over a period of one hour in-subject. Our thesis was that if the response to captopril
had a duration longer than we anticipated, it would have creases RPF and also increases the response to pharma-
cological interruption with ACE inhibitors and Ang IIbeen expressed in baseline PRA level and RPF prior to
candesartan administration. As both measures were es- antagonists [26, 27]. This paradoxical relationship, a
larger renal vasodilator response to pharmacological in-sentially identical at baseline on the two days, it is un-
likely that a sustained action of captopril influenced the terruption of the renin system being associated with
higher RPF at baseline, was evident not only in our pa-results. However, despite this observation, the possibility
of a carryover effect cannot be ruled out with certainty. tients with type 1 diabetes in this study, but also in patients
with type 2 diabetes and nephropathy as we have re-There is evidence of RAS activation in diabetic sub-
jects who are hyperglycemic. In Miller et al’s study on ported recently [37]. Thus, it is possible that the forces
responsible for vasodilation and the forces responsibletype 1 diabetic patients, hyperglycemia produced higher
PRA levels compared with euglycemia, both at baseline for activation of the intrarenal RAS are in some way
related. Studies by our group are currently being under-when patients were lying supine and during periods of
orthostatic stress induced by lower body negative pres- taken to investigate the factors determining the level of
baseline RBF (abstract; Laffel et al, J Am Soc Nephrolsure [35]. To assess further the implications for the kid-
ney of the RAS activation in patients with type 1 diabetes, 9:117a, 1998). The possibility of genetic determinants,
for example ACE gene polymorphisms, is especially at-the same investigator reported decreased baseline effec-
tive RPF (ERPF) and renal blood flow (RBF) after in- tractive, although the present study was not powered to
address this issue. In animal studies, the renal hemody-ducing hyperglycemia over a period of approximately
12 hours and a significant increase in ERPF upon admin- namic response to hyperglycemia has been attributed,
at least in part, to activation of nitric oxide synthase [38].istration of the Ang II antagonist losartan while main-
taining a hyperglycemic state. There was no significant Moreover, there has been substantial recent interest in
a continuing interaction between nitric oxide and RASchange in either ERPF or RBF during euglycemia [36].
These experiments support the hypothesis that hypergly- as part of normal renal homeostasis [39].
How does hyperglycemia activate the RAS? Onecemia affects renal hemodynamics by activating the RAS.
Activation of the RAS in these subjects with type 1 might invoke a reduced extracellular fluid volume from
osmotic diuresis as the mechanism. Other studies, how-diabetes suggested strongly by the highly concordant
renal hemodynamic response to captopril and to cande- ever, show no evidence of intravascular volume deple-
tion during hyperglycemia [32, 40]. In a study by Woods,sartan was not evident in measures of PRA. By this index
the renin system was suppressed, as anticipated, from Mizelle, and Hall, a tubuloglomerular feedback mecha-
nism was implicated since intrarenal infusion of glucosethe high-salt intake. These observations suggest the pos-
Lansang et al: Captopril and candesartan 1437
8. Zatz R, Meyer TW, Rennke HG, et al: Predominance of hemody-in rats resulted in an increased renin secretion rate to
namic rather than metabolic factors in the pathogenesis of diabetic
greater than twice the control level, but only in filtering glomerulopathy. Proc Natl Acad Sci USA 82:5963–5967, 1985
9. Zatz R, Dunn BR, Meyer TW, et al: Prevention of diabetic glomer-kidneys [41].
ulopathy by pharmacological amelioration of glomerular capillaryThe remarkable concordance in the renal hemody-
hypertension. J Clin Invest 77:1925–1930, 1986
namic response to the ACE inhibitor captopril and the 10. Remuzzi A, Perico N, Amuchastegui CS, et al: Short- and long-
term effect of angiotensin II receptor blockade in rats with experi-AT1 receptor blocker candesartan makes it exceedingly
mental diabetes. J Am Soc Nephrol 4:40–49, 1993likely that the exaggerated response reflects reversal of
11. Pollock DM, Divish BJ, Polakowski JS, et al: Angiotensin II
an increase in angiotensin-mediated renal vascular tone. receptor blockade improves renal function in rats with reduced
renal mass. J Pharmacol Exp Ther 267:657–663, 1993That, in turn, probably reflects an increase in Ang II
12. Bjorck S, Herlitz H, Nyberg G, et al: Effect of captopril on renalgeneration as the mediator. The absence of an increase
hemodynamics in the treatment of resistant renal hypertension.
in PRA in the patients who show the enhanced response Hypertens Suppl 5:152–153, 1983
13. Abu-Romeh SH, Nawaz MK, Ali JH, et al: Short-term effectpoints to intrarenal Ang II generation as the probable
of angiotensin-converting-enzyme inhibitor enalapril in incipientlocus, in accord with observations that we have made in
diabetic nephropathy. Clin Nephrol 31:18–21, 1989
patients with type 2 diabetes mellitus and in normal 14. Baba T, Murabayashi S, Takebe K: Comparison of the renal
effects of angiotensin-converting-enzyme inhibitor and Ca antago-subjects during infusion of glucose to maintain a stable
nist in hypertensive type 2 (non-insulin-dependent) diabetic pa-level of hyperglycemia below the threshold for glycosuria tients with microalbuminuria: A randomized controlled trial. Dia-
[26, 27, 42]. Activation of the intrarenal RAS in patients betologia 32:40–44, 1989
15. D’Angelo A, Sartori L, Gambaro G, et al: Captopril in the treat-with diabetes provides a powerful rationale for the effec-
ment of hypertension in type 1 and type 2 diabetic patients. Post-tiveness of therapeutic agents that block this system. The grad Med J Suppl 62:69–72, 1986
specific factors responsible for activation of the RAS 16. Drummond K, Levy-Marchal C, Laborde K, et al: Enalapril does
not alter renal function in normotensive, normoalbuminuric, hyp-beyond hyperglycemia and the implications of this acti-
erfiltering type 1 (insulin-dependent) diabetic children. Diabeto-vation on the pathogenesis of nephropathy both require logia 32:255–260, 1989
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